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Previous Presentations: Parts of the results were presented at the 10th IAS conference, 21-
24 July 2019 in Mexico. 
 
Summary: We assessed changes in renal function after replacing TDF with TAF in a national 
cohort of HIV-infected individuals. Among patients with established renal dysfunction, 






















Replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafenamide (TAF) improves 
renal tubular markers in HIV-infected individuals, but the impact on estimated glomerular 
filtration rate (eGFR) remains unclear. 
Methods 
We included all participants from the Swiss HIV Cohort Study who switched from a TDF to a 
TAF-containing antiretroviral regimen or continued TDF. We estimated changes in eGFR 
and urine protein-to-creatinine ratio (UPCR) after 18 months using mixed-effect models. 
Results 
Of 3’520 participants (26.6% women, median age 50 years), 2’404 (68.5%) switched to TAF. 
Prior to switch, 1’664 (47.3%) had an eGFR <90 mL/min, and 1’087 (30.9%) a UPCR ≥15 
mg/mmol. In patients with a baseline eGFR ≥90 mL/min, eGFR decreased with the use of 
TDF and TAF (-1.7 ml/min). Switching to TAF was associated with increases in eGFR of 1.5 
mL/min (95% CI 0.5–2.5) if the baseline eGFR was 60-89 mL/min, and 4.1 mL/min (95% CI 
1.6–6.6) if <60 mL/min. In contrast, eGFR decreased by 5.8 mL/min (95% CI 2.3–9.3) with 
the continued use of TDF in individuals with a baseline eGFR <60 mL/min. UPCR decreased 
after replacing TDF by TAF, independent of baseline eGFR. 
Conclusions 
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Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor (NRTI) 
included in many first-line antiretroviral therapy (ART) regimens, and has been associated 
with renal side effects such as proximal renal tubulopathy and Fanconi syndrome [1-3]. 
Tenofovir alafenamide (TAF), a prodrug that reaches high intracellular tenofovir 
concentrations while maintaining 90% lower plasma levels than TDF, seems less likely to 
cause proximal renal tubulopathy [4-6]. Therefore, current ART guidelines favor TAF over 
TDF as a component of ART for HIV-infected patients who are at risk for kidney disease [7, 
8]. 
Whereas the beneficial impact of TAF on markers of proximal renal tubulopathy seems clear, 
studies reporting changes in estimated glomerular filtration rate (eGFR) have shown mixed 
results [5, 6, 9-11]. However, patients with co-morbidities and established renal dysfunction 
were generally underrepresented in these studies. A phase three study assessed the impact of 
replacing TDF by TAF on renal function and did not show any improvement in eGFR after 
48 and 96 weeks [12, 13]. Furthermore, the single-arm design of the trials enrolling patients 
with renal dysfunction did not allow the comparison of changes in renal function between 
patients on TDF and TAF. Finally, whether the impact of replacing TDF by TAF varies among 
patients with comorbidities other than renal dysfunction is unknown. 
We used data from the Swiss HIV Cohort Study (SHCS) to estimate the impact of replacing 
TDF by TAF on eGFR and proteinuria, and assessed whether differences exist among 




The SHCS (www.shcs.ch) is a prospective multicenter cohort that enrolls close to 80% of all 
HIV-infected adults currently receiving ART in Switzerland [14]. Clinical and HIV-specific 
data as well as laboratory values are recorded at enrollment, and every 6 months thereafter. 
In addition to protocol-defined assessments, laboratory data from additional visits and 
hospitalizations at the study sites are also registered. All changes in ART and co-medications 
are recorded, and stopping reasons are required when any drug is changed. Local ethical 
committees of all cohort centers approved this cohort study and all patients provided a 
written informed consent. 
We considered all participants with follow-up visits after January 1st 2016. Patients had to be 
on a TDF-containing ART for more than 30 days and (a) continue TDF until the end of the 
observation period (March 2019), or (b) switch from TDF to TAF. The decision to switch was 
at the discretion of the treating physician. We restricted our analyses to direct switches from 
TDF to TAF and excluded patients who were prescribed other NRTIs in between. 
Additionally, patients who discontinued TAF after the switch were excluded, but we explored 
related causes using stopping reasons given by the treating physician. Finally, to be included, 
patients needed to have at least two creatinine measurements before baseline and two 
measurements thereafter, with a minimum of one month interval between each other. The 
baseline date was defined as (a) switching date for patients on TAF, (b) October 1st 2016 for 
patients remaining on TDF (date of introduction of TAF into the Swiss market), or (c) 


















Outcomes and definitions 
Our primary outcome was the change in eGFR between baseline and 18 months thereafter. 
We considered all available creatinine measurements 24 months before and 18 months after 
baseline date, and used the CKD-EPI equation to calculate the eGFR [15]. The main exposure 
of interest was switching from TDF to TAF compared to remaining on TDF. Secondary 
outcomes were improvements in eGFR ≥10% from baseline, and changes in proteinuria 
(expressed as urine protein-to-creatinine ratio in mg/mmol, normal value <15 mg/mmol). 
Arterial hypertension was defined as two measurements >140/90 mmHg or current 
antihypertensive treatment, diabetes mellitus as HbA1c ≥6.5% or current antidiabetic 
treatment, and osteoporosis as a T-score ≤-2.5 in any bone density measurement or history 
of fragility fracture. Chronic hepatitis B virus (HBV) infection was defined as the presence of 
a positive hepatitis B surface (HBs) antigen, and hepatitis C infection (HCV) as having a 
detectable HCV viral load at any time-point, irrespective of HCV treatment. A history of 
cardiovascular disease included the past occurrence of myocardial infarction, cerebral 
infarction, coronary angioplasty/stenting, coronary artery bypass grafting, venous 
thromboembolic events, or any procedure on peripheral arteries. 
Statistical analyses 
We compared patient characteristics between individuals who switched to TAF and those 
who remained on TDF using Fisher’s exact and Wilcoxon rank-sum tests. We calculated 
mean changes (with 95% confidence intervals [CI]) in eGFR between baseline and 18 months 
thereafter, and used linear mixed-effect models to analyze the impact of switching from TDF 
to TAF on eGFR and proteinuria. Multivariable analyses were adjusted for the following 
factors at baseline: age, sex, African origin, CD4 cell count (categorized as above or below 
500 cells/µL), time since TDF start, history of cardiovascular disease, arterial hypertension, 
diabetes, and infection with HBV or HCV. Since several drugs lead to higher serum 
creatinine levels through reduced creatinine secretion, the use of ritonavir, cobicistat, 
dolutegravir or cotrimoxazole were included as time-varying covariates in the eGFR analysis 
[16-18]. To account for non-linearity, we added time from baseline as a linear and quadratic 
term. We hypothesized that the impact of switching from TDF to TAF on eGFR differed 
according to eGFR at baseline (categorized as ≥ 90 mL/min, 60–89 mL/min and <60 
mL/min), and included this parameter as an interaction term. Residual effects within 
categories of this variable were accounted for using a variable indicating the quartiles within 
each eGFR category at baseline. All covariates were tested for interaction with time and 
eGFR, but no other interaction terms were statistically significant. For proteinuria, we 
identified age, sex, African origin, diabetes, arterial hypertension and eGFR at baseline as 
potential confounders, and adjusted for them in our model. Additionally, we included an 
interaction term for eGFR at baseline (categorized as above) to explore the impact on 
proteinuria among these categories. All statistical analyses were performed using Stata 15.1 





















Since the inclusion of clinically indicated creatinine measurements (e.g. in the event of acute 
renal failure) could lead to an accumulation of high creatinine values that are not necessarily 
representative of the long-term renal function trajectory, we performed a sensitivity analysis 
which included only measurements taken at per-protocol cohort visits, every 6 months. The 
exclusion of patients with less than two creatinine measurements and those who switched 
from TDF to a different NRTI than TAF could have led to the overestimation of the impact of 
switching. Therefore, we performed an analysis including all individuals with any number of 
creatinine measurements, and including those who switched from TDF to a different NRTI 
after the baseline date. These individuals were categorized into the TDF group, and eGFR 
values were censored at the time of switch to a different NRTI. To minimize the potential 
impact of other ART changes on changes in eGFR, we performed an additional analysis 
including only individuals without any further ART changes other than the replacement of 
TDF with TAF after baseline. Finally, we explored the impact of co-administering boosted 
protease inhibitors (PI) with TDF and TAF using an interaction term indicating whether 
patients were on such a regimen at baseline. 
RESULTS 
Study population 
Of 10’482 patients with active follow-up during the study period, 8’198 ever received TDF. 
For our main analyses, we excluded 3’129 individuals who switched from TDF to another 
NRTI, 80 who switched to TAF but discontinued TAF during the study period, and 1’469 who 
did not have enough creatinine measurements, leaving a study population of 3’520 patients 
(Figure S1). Of those, 2‘407 (68%) had switched from TDF to TAF. Overall, 938 (26.6%) 
patients were women, the median age was 50 years (interquartile range [IQR] 43 to 56), and 
535 (15.2%) were of African origin. HBV-coinfection was present in 243 (7.2%) individuals, 
and HCV infection in 448 (12.9%), of whom 75 (2.3% overall) had a detectable HCV-RNA at 
baseline. The median eGFR at baseline was 91.4 mL/min (IQR 77.5 to 104.2); 1’664 patients 
(47.3%) had an eGFR below 90 mL/min, and 194 (5.5%) had an eGFR below 60 mL/min. 
Baseline characteristics by switch status are shown in Table 1. Patients who switched to TAF 
were older, less likely to be female or of African origin, and had a lower eGFR at baseline. 
Patients in the TAF group were more likely to have comorbidities such as arterial 
hypertension, diabetes, cardiovascular diseases or osteoporosis, and were more likely to be 
on an integrase inhibitor or PI-based ART regimen at baseline. Median follow-up time was 
similar in both groups (15.5 months for patients remaining on TDF vs. 14.7 months for those 
who switched to TAF), but the exposure to TDF before baseline was 1.1 year longer in those 
who switched to TAF compared to those remaining on TDF. Median eGFR at baseline was 
higher in the TDF group than in the TAF group (96.9 mL/min, IQR 83.4 to 108.3 vs. 89.0 
mL/min, IQR 75.1 to 102.1, p<0.0001). Of all patients included in our analysis, 3’036 
(86.3%) had proteinuria measurements available at baseline. The proportion of individuals 
with a urine protein-to-creatinine ratio ≥15 mg/mmol as well as median urine protein-to-
creatinine ratio at baseline were similar between those who remained on TDF and those who 



















Changes in eGFR over time 
From baseline to 18 months thereafter, eGFR decreased by 1.7 mL/min (95% CI 0.8 to 2.7) in 
individuals who remained on TDF, and increased by 0.3 mL/min (95% CI -0.5 to 1.0) in 
those who switched to TAF. In multivariable analyses, switching from TDF to TAF was 
associated with a decrease in eGFR for patients with an eGFR at baseline ≥90 mL/min, and 
with an increase for patients with a baseline eGFR of 60–89 mL/min and below 60 mL/min 
(Figure 1, Table 2). Switching from TDF to TAF was associated with a predicted change in 
eGFR of -1.7 mL/min (95% CI -2.7 to -0.8) for patients with a baseline eGFR ≥90 mL/min, 
1.5 mL/min (95% CI 0.5 to 2.5) for those with an eGFR of 60–89 mL/min, and 4.1 mL/min 
(95% CI 1.6 to 6.6) for individuals with an eGFR <60 mL/min. Patients remaining on TDF 
experienced a decrease in eGFR, irrespective of the eGFR at baseline, with the most 
prominent decrease seen among individuals with an eGFR <60 mL/min (Table 2).  
Predictors of an increase in eGFR 
Among patients who switched to TAF with a baseline eGFR below 90 mL/min, the likelihood 
of improving their eGFR of ≥10% after 12 months was similar among patients with different 
comorbidities and whether ART regimens included boosted protease inhibitors (PI) at 
baseline or not. Older individuals were less likely to improve their eGFR (adjusted odds 
ratio: 0.86 per 10 year step, 95% CI 0.72 to 1.01). When we restricted the analysis to 
individuals with an eGFR <60 mL/min, those on a boosted PI regimen were 50% less likely 
to experience an improvement of ≥10% after 12 months (Figure 2). 
Changes in proteinuria 
Crude and adjusted changes in proteinuria from baseline are shown in Figure 3. In patients 
remaining on TDF, urine protein-to-creatinine ratio remained stable at 18 months (0.7 
mg/mmol, IQR -3.8 to 9.0), whereas it decreased in patients who switched to TAF (2.2 
mg/mmol, IQR 1.5 to 8.0). In adjusted analyses, the urine protein-to-creatinine ratio 
increased by 3.1 mg/mmol (95% CI 0.4 to 5.8) in those who remained on TDF, compared to a 
decrease of 6.1 mg/mmol (95% CI 4.3 to 7.8) in patients who switched to TAF, 18 months 
after baseline. The decrease in urine protein-to-creatinine ratio after switching to TAF was 
most prominent in the group of patients with baseline eGFR measurements <60mL/min 
(15.5 mg/mmol, 95% CI 8.3 to 22.7), and in those with an eGFR 60–89 mL/min (7.1 
mg/mmol, 95% CI 4.5 to 9.6) (Figure S2). 
Reasons for discontinuation of TAF 
Eighty individuals had TDF replaced by a TAF, but subsequently stopped it before the end of 
the observation period. The most common reasons given by the treating physician were “use 
of a study treatment” (n=16, 20%), “simplified treatment available” (n=11, 13.8%) and 
“patient’s wish”, which included ART discontinuation (n=10, 12.5%). Other reasons were 
“drug interactions” (n=4, 5%), “intended pregnancy” (n=3, 3.8%) and “treatment failure” 
(n=2, 2.5%). Toxicity accounted for 10 discontinuations (12.5%), with only one being 
attributed to renal toxicity (Table S1). The latter patient experienced renal dysfunction and 
proteinuria over time using TDF, which improved slightly after changing to TAF, but ART 



















After restricting our analysis to creatinine values taken at pre-specified cohort visits, neither 
the slope nor the magnitude of creatinine trajectories changed substantially (mean number 
of creatinine measurements 6.1 vs. 11.7 in the full analysis dataset, Figure S3). 
Furthermore, including all patients irrespective of the number of available creatinine 
measurements and those who switched from TDF to a different NRTI than TAF after the 
baseline date did not change our findings (Table S2). No substantial changes could be 
observed after restricting the analysis to individuals without any additional changes made to 
their ART regimen other than replacement of TDF with TAF (973 [87.4%] of those remaining 
on TDF, and 1’220 [50.7%] of those switching to TAF, Table S3). In analyses stratified 
according to the use of a boosted PI at baseline, predicted changes in eGFR remained similar 
among individuals with a baseline eGFR ≥90 mL/min or 60–89 mL/min. However, the use 
of boosted PIs in patients with an eGFR below 60 mL/min who remained on TDF was 
associated with an eGFR decrease of 23.0 mL/min (95% CI 11.1 to 34.8) at 18 months, 
whereas the eGFR of those who switched to TAF remained stable at 18 months (1.6 mL/min, 
95% CI -2.9 to 6.1). In contrast, individuals with an eGFR below 60 mL/min who switched to 




In this nationwide cohort of HIV-infected individuals, the eGFR and urine protein-to-
creatinine ratio improved among individuals with pre-existing renal dysfunction after 
switching from TDF to TAF, whereas these markers remained stable among patients without 
renal dysfunction. Our results support international guidelines recommending the 
replacement of TDF by TAF in individuals with renal dysfunction. 
Most clinical trials have shown improvements in renal tubular markers on TAF-containing 
regimens compared to TDF, but failed to show significant changes in eGFR. Over time, 
ongoing tubular toxicity leads to the inflammation of the renal tubules, followed by a 
progressive loss of tubular cells and destruction of other renal structures, eventually 
reflected in the decreasing eGFR [19]. In our study, replacing TDF by TAF was not only 
followed by reductions in proteinuria, but also by an increase in eGFR among individuals 
with established renal dysfunction. These findings were independent of co-existing 
infections, cardiovascular or metabolic diseases. The magnitude of the improvements in both 
eGFR and proteinuria was highest in the group of patients with pre-established renal 
dysfunction who switched to TAF, suggesting a link between this specific treatment change 
and the partial reversal of TDF-induced tubular toxicity. Our findings contrast with previous 
studies in which improvements in renal function were mainly limited to decreases in renal 
tubular markers [5, 6, 9, 20]. Among 242 HIV-infected patients with renal impairment 
(eGFR of 30 to 69 mL/min) who switched to a TAF-based ART regimen, no significant 
change in eGFR was found at 48 and 96 weeks [12, 13]. These discrepancies could be 
attributed to the larger and more representative patient population of our study, including 
individuals with comorbidities and renal dysfunction. In line with our findings, a recent 
pooled analysis of 26 clinical trials comparing TDF and TAF found improvements in eGFR as 
well as renal tubular markers [21]. However, the latter study enrolled few individuals with 


















The decline in eGFR among patients with a normal renal function at baseline was similar 
between patients on TDF and those switched to TAF, and was comparable to the 
physiological eGFR decline seen in ageing, healthy individuals [22]. These findings confirm 
and extend earlier results of a meta-analysis and a large observational study, in which renal 
adverse events were rare when TDF was given to individuals without renal dysfunction [2, 3]. 
In line with the results of previous studies, switching to TAF was associated with 
improvements in proteinuria among our study participants, irrespective of the eGFR at 
baseline [5, 6, 20]. Nevertheless, the renal benefit of replacing TDF by TAF in individuals 
with a normal eGFR but with proteinuria remains to be determined. 
The use of TDF in combination with a boosted PI has been associated with a more 
pronounced decline in eGFR and higher rates of treatment discontinuations due to renal 
events, compared to regimens including TDF and another third agent [23, 24]. Protease 
inhibitors increase tenofovir plasma levels, which might lead to enhanced renal toxicity [25]. 
In line with those findings, individuals with renal dysfunction who continued TDF together 
with a boosted PI in our study experienced a marked decline in eGFR. However, patients on 
boosted PIs with an eGFR <60 mL/min who switched to TAF were less likely to improve 
their eGFR after 12 months compared to those without PIs. This finding has been replicated 
in earlier studies assessing changes in eGFR after stopping TDF, which suggested that renal 
function recovery takes longer in these individuals [26, 27]. This finding warrants 
confirmation in other studies, as this subgroup of patients was small.  
Our study provides robust evidence on the renal benefits of replacing TDF by TAF among 
individuals with renal dysfunction on TDF, independent of the presence of other 
comorbidities. The association between the switch to TAF and eGFR changes remained 
significant across a range of sensitivity analyses. In contrast to most studies having explored 
the association between TAF and renal outcomes within clinical trials, ours is based on real 
world data from a nationally representative cohort, which consists of an ageing population 
with a high prevalence of non-communicable diseases [28]. Additionally, the considerable 
amount of individuals using TDF with renal dysfunction provided a unique opportunity to 
have a comparison group for our analyses. However, given the short follow-up time available 
on TAF-containing regimens, we were not able to provide evidence of a long-term benefit of 
TAF on renal function. Furthermore, time spent on TDF before baseline was slightly longer 
for patients switching to TAF compared to those remaining on TDF. In order to minimize the 
potential underestimation of the renal benefit of switching to TAF ,we included time on TDF 
before baseline in our multivariable analysis. Although we adjusted our multivariable models 
for the most important comorbidities and co-medications, the presence of other factors such 
as nephrotoxic drugs or other renal diseases might have led to the underestimation of the 
improvement in renal function after the switch from TDF to TAF. Since we used a single 
eGFR measurement for baseline stratification, we could not exclude the presence of 
regression to the mean. However, the similarity between the results obtained by using all 
available eGFR measurements for each patient (11.7 on average) and those seen when using 
only semi-annual, per-protocol measurements (6.1 on average), was reassuring in this 
regard. Finally, subgroup analyses, such as the one focusing on individuals treated with 
boosted protease inhibitors, were based on a small number of observations, and should 
therefore be regarded as exploratory. 
In conclusion, our findings suggest that switching from TDF to TAF or to another TDF-free 
backbone should be considered in individuals with established renal dysfunction. In the 
absence of other risk factors for TDF-associated toxicity, continuing TDF in individuals with 


















due to the availability of generic formulations of TDF. Additionally, since TAF seems to be 
associated with other adverse events such as increases in cholesterol levels and weight gain, 
longer-term follow-up from observational cohort studies is needed to confirm the safety and 
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Table 1: Baseline characteristics of the study population 
 
Remained on TDF 
n = 1’113 
Switched to TAF 
n = 2’407 
 
p-value 
Female sex (%) 359 (32.3) 579 (24.1) <0.0001 
Median age in years (IQR) 48 (41–54) 51 (43–57) <0.0001 
African origin (%)  227 (20.4) 308 (12.8) <0.0001 
Transmission group (%)   <0.0001 
MSM 440 (40.8) 1195 (50.8)  
PWID 98 (9.1) 253 (10.8)  
other 541 (50.1) 903 (38.4)  
Median CD4 count in cells/µL (IQR) 628 (485–816) 646 (487–835) 0.16 
Median CD4 nadir in cells/µL (IQR) 219 (111–314) 204 (106–309) 0.15 
Chronic HBV infection (%) 80 (7.5) 163 (7.1) 0.70 
Chronic HCV infection (%) 138 (12.5) 310 (13.1) 0.70 
History of CV disease (%) 80 (7.2) 227 (9.4) 0.03 
Diabetes (%) 64 (5.8) 185 (7.7) 0.04 
Arterial hypertension (%) 590 (53.0) 1444 (60.0) <0.0001 
Osteoporosis (%) 42 (3.8) 179 (7.4) <0.0001 
Median eGFR in mL/min (IQR) 96.9 (83.4–108.3) 89.0 (75.1–102.1) <0.0001 
eGFR category (%)   <0.0001 
≥90 mL/min 701 (63.0) 1155 (48.0)  
60-89 mL/min 389 (35.0) 1081 (44.9)  
<60 mL/min 23 (2.1) 171 (7.1)  
Median urine protein-to-creatinine ratio (IQR) 11.5 (7.6–21.0) 11.5 (7.8–20.0) 0.99 
Urine protein-to-creatinine category (%)   0.87 
<15 mg/mmol 554 (49.8) 1395 (58.0)  
15-50 mg/mmol 226 (20.3) 576 (23.9)  
>50 mg/mmol 85 (7.6) 200 (8.3)  
Missing 248 (22.3) 236 (9.8)  
Median time on TDF before baseline in years (IQR) 7.1 (4.7–10.3) 8.2 (5.2–11.0) <0.0001 
Third drug at baseline   <0.0001 
Boosted protease inhibitor (%) 173 (15.5) 749 (31.1)  


















NNRTI (%) 825 (74.1) 802 (33.3)  
TDF = Tenofovir disoproxil fumarate, TAF = Tenofovir alafenamide, IQR = interquartile range, MSM = men who have sex 
with men, PWID = patients who inject drugs, HBV = hepatitis B virus, HCV = hepatitis C virus, CV = cardiovascular, eGFR = 


















Table 2: Predicted mean eGFR (95% confidence interval) over time according to the multivariable model 1 
 eGFR at baseline ≥90 mL/min  eGFR at baseline 60–89 mL/min  eGFR at baseline below 60 mL/min 
 TDF (n = 701) TAF (n = 1’155)  TDF (n = 389) TAF (n = 1’081)  TDF (n = 23) TAF (n = 171) 
eGFR at baseline* 101.9 (101.5 to 102.4) 103.6 (102.8 to 104.5)  80.8 (80.3 to 81.2) 81.9 (81.0 to 82.8)  59.9 (58.6 to 61.2) 63.5 (61.2 to 65.8) 
eGFR after 18 months 100.2 (99.5 to 101.0) 101.9 (100.9 to 102.9)  79.8 (78.8 to 80.8) 83.4 (82.4 to 84.4)  54.1 (50.2 to 58.0) 67.6 (65.0 to 70.1) 
Change in eGFR after 18 months -1.7 (-2.4 to -1.0) -1.7 (-2.7 to -0.8)  -0.9 (-1.8 to -0.1) 1.5 (0.5 to 2.5)  -5.8 (-9.3 to -2.3) 4.1 (1.6 to 6.6) 
Difference in eGFR of TAF vs. 
TDF after 18 months 
-0.1 (-1.3 to 1.2)  2.5 (1.1 to 3.8)  9.9 (5.6 to 14.2) 
Predicted changes (with 95% confidence intervals) using a mixed effect model, adjusted for age, sex, ethnicity, CD4 cell count at baseline, time since TDF start, use of ritonavir, cobicistat, 
dolutegravir or cotrimoxazole, presence of cardiovascular disease, arterial hypertension, diabetes, dyslipidemia and co-infection with hepatitis B and hepatitis C virus. 
eGFR = estimated glomerular filtration rate, TDF = tenofovir disoproxil fumarate, TAF = tenofovir alafenamide 


















FIGURE LEGENDS 2 
Figure 1: Predicted change (95% confidence interval) in eGFR over time 3 
Stratified by eGFR at baseline. Predicted changes (with 95% confidence intervals) using a mixed effect model, 4 
adjusted for age, sex, ethnicity, CD4 cell count at baseline, use of ritonavir, cobicistat, dolutegravir or 5 
cotrimoxazole, presence of cardiovascular disease, arterial hypertension, diabetes, dyslipidemia and co-infection 6 
with hepatitis B and hepatitis C virus. 7 
 eGFR = estimated glomerular filtration rate, TDF = tenofovir disoproxil fumarate, TAF = tenofovir alafenamide 8 
 9 
Figure 2: Predictors of an eGFR increase of ≥10% from baseline after 12 months in patients 10 
who switched to TAF (multivariable model) 11 
Panel A: Patients on TAF with an eGFR at baseline <90 mL/min (n = 1’081).  12 
Panel B: Patients on TAF with an eGFR at baseline <60mL/min (n = 171). * Per +10 years older. 13 
CV = cardiovascular, HBV = hepatitis B virus, HCV = hepatitis C virus, PI = protease inhibitor 14 
 15 
Figure 3: Change in proteinuria over time 16 
Line/Ribbon: Predictions (95% confidence interval) using a mixed effect model (adjusted for sex, age, African 17 
origin, presence of diabetes, arterial hypertension and eGFR at baseline) 18 
 19 
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